
Major breakthrough as 10 patients have their diabetes CURED with new drug
Ten people have been effectively cured of their type 1 diabetes after a breakthrough infusion of stem cells on the path toward FDA approval.
One year after being treated, 10 of the 12 patients who took the drug, called Zimislecel, no longer needed insulin, while the other two needed much smaller doses.
The groundbreaking therapy's foundation uses stem cells that researchers manipulated to become pancreatic islet cells, tiny clusters of specialized cells scattered throughout the pancreas that produce hormones to regulate blood sugar.
The cells were injected into the patients, traveling through the liver, implanted there, and began producing insulin where their bodies had previously produced none.
Their blood sugar spikes were less severe after meals. Their insulin production also kept improving, and their time spent in a healthy glucose range went from about 50 percent at baseline to over 93 percent at one year.
The study's participants are among the 30 percent of type 1 diabetes patients with a complication that makes it impossible for them to tell when their blood sugar is low or high, lacking the normal signs like shakiness or sweating.
All of the patients in the study had this subtype of type 1, known as hypoglycemic unawareness. The condition can also cause patients to pass out, have seizures, or even die.
Researchers behind the study believe their drug paves the way toward a cure for type 1 diabetes overall. The condition, which is due to a combination of genetics and environmental factors like childhood viral infections, affects roughly 1.6 million Americans.
Trevor Reichman, a study co-author and surgeon at University Health Network in Toronto, told STAT: 'This study represents for the first time that biologic replacement can be administered to patients with type 1 diabetes in a single safe and effective procedure with minimal risk to the recipient.'
'This study has the potential to get us one step closer to a 'functional cure' for patients with type 1 diabetes,' Reichman added.
Researchers expect to apply for approval of this drug with the FDA within the next five years.
Patients had to have a history of hypoglycemic unawareness to participate in the study, causing seizures, coma, loss of consciousness, or hospital stays.
Once they started taking Zimislecel, made by Vertex Pharmaceuticals of Boston, the patients also had to take immune-suppressing drugs to prevent the body from attacking the foreign islet cells.
One study enrollee, Amanda Smith, 36, from London, told the New York Times that she jumped at the chance to join the groundbreaking trial.
Six months after receiving the infusion, she no longer needed insulin.
'It's like a whole new life,' she said.
Traditionally, stem cells are isolated from the pancreas of a deceased organ donor. However, the cells in the latest research were grown in the lab rather than taken from cadavers, offering a scalable, renewable source of islet cells without having to rely on a limited supply of donors.
Type 1 is less common than type 2 diabetes, which affects 32 million Americans and typically comes on later in life due to a confluence of lifestyle factors and genes.
Without insulin, type 1 diabetics' bodies have no way to regulate blood sugar, which can build up in the bloodstream and skyrocket.
The body starts breaking down fat for fuel, creating ketones, or acidic byproducts. A buildup of ketones in the blood can cause diabetic ketoacidosis, a condition that causes nausea, vomiting, rapid breathing, dehydration, and confusion.
Without proper treatment with insulin and fluids, diabetic ketoacidosis can cause a laundry list of potentially fatal effects, including brain swelling, kidney failure, cardiac arrest, and death.
This therapy is 25 years in the making, pioneered by the father of a baby who was diagnosed with type 1 diabetes, followed by his teen daughter. He pledged to find a cure for the disease.
Their findings were published in the New England Journal of Medicine.
The first patient to receive this therapy was Brian Sheton, who got it in 2021. He had been living with low blood sugar that often plunged him into a state of unconsciousness, even crashing his motorcycle into a wall at one point.
The infusion cured him, but Vertex said he died afterward due to dementia symptoms that were present before he was treated.
Stem cell therapy is the newest frontier in disease research, starting with niche conditions, such as hypoglycemic unawareness. Still, it has the potential to be scaled up to cover a broader umbrella of diseases.
After 25 years of taking insulin shots, Illinois mom Marlaina Goedel finally said what she had longed to say for years: 'I am cured.'
The 30-year-old was diagnosed with type 1 diabetes at five, and became one of a handful of people to have received an islet cell transplant.
Her blood sugar normalized within a month after the infusion, and she no longer needed insulin injections.
Now, she's chasing long-postponed dreams: riding her horse, going back to school, and soaking in the sweetness of a life no longer dictated by blood sugar numbers.
'We hope in the next five to 10 years that this therapy will have the potential to be given with minimal or zero immunosuppression, further minimizing the risk for patients long-term,' Dr Reichman said, adding that more research is still needed on a larger population.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


BBC News
35 minutes ago
- BBC News
How dem make anti-venom from man wey snake bite 200 times
Di blood of one US man wey deliberately inject imsef wit snake venom for nearly twenty years don lead to "unparalleled" anti-venom, scientists tok. Antibodies find in Tim Friede blood don shown to protect against deadly doses from one wide range of species in animal tests. Current therapies gatz match di specific species of venomous snake wey bite anyone. But Oga Friede 18-year mission fit lead to ogbonge step of finding universal anti-venom against all snakebites - wey dey kill up to 140,000 pipo evri year and leave three times as many needing amputations or facing permanent disability. In total, Mr Friede don endure more dan 200 bites and more dan 700 injections of venom e prepare from some of di world deadliest snakes, including multiple species of mambas, cobras, taipans and kraits. E bin want build up im immunity to protect imsef wen e dey handle snakes, documenting im exploits on YouTube. But di former truck mechanic tok say e don "completely screw up" early on wen two cobra bites wey happun in quick succession leave am in coma. "I no wan die. I no wan lose one finger. I no wan miss work," e tell BBC. Oga Friede motivation na to develop beta therapies for di rest of di world, explaining: "E just become lifestyle and I just keep pushing and pushing and pushing as hard as I fit push - for di pipo wey dey 8,000 miles away from me wey don die from snakebite". 'I go love to get my hands on some of your blood' Currently dem dey make anti-venom by injecting small doses of snake venom into animals, such as horses. Dia immune system dey fight di venom by producing antibodies and dem go harvest am to use as therapy. But venom and anti-venom gatz dey closely matched becos di toxins for venomous bite no be di same from one species to anoda. Dem even get wide variety within di same species – anti-venom wey dem make from snakes from India dey less effective against di same species for Sri Lanka. One team of researchers begin dey search for one type of immune defence wey dem dey call broadly neutralising antibodies. Instead of targeting di part of toxin wey make am unique, dem dey target di part wey make am common to entire classes of toxin. Dat na wen Dr Jacob Glanville, chief executive of biotech company Centivax, come across Tim Friede. "Immediately I look say 'if anybody in di world don develop dis broadly neutralising antibodies, e go be am' and so I reach out," e tok. "Di first call, I be like 'dis fit dey awkward, but I go love get my hands on some of your blood'." Oga Friede agree and di work dey ethically approved becos di study go only take blood, rather dan give am more venom. Di research focus on elapids – one of di two families of venomous snakes – such as coral snakes, mambas, cobras, taipans and kraits. Elapids primarily use neurotoxins in dia venom, wey dey paralyse dia victim and e dey fatal wen dem stop di muscles e need to breathe. Researchers don pick 19 elapids identify by di World Health Organization as being among di deadliest snakes on di planet. Dem don begin to source for Oga Friede blood for protective defences. Dia work, dey detailed in di journal Cell, identify two broadly neutralising antibodies wey fit target two classes of neurotoxin. For experiments on mice, di cocktail mean say di animals bin survive deadly doses from 13 of di 19 species of venomous snake. Dem bin get partial protection against di remaining six. Dis na "unparalleled" breadth of protection, according to Dr Glanville, wey say e "likely cover a whole bunch of elapids for wey no get current anti-venom". Di team dey try to refine di antibodies further and see if adding fourth component fit lead to total protection against elapid snake venom. Di oda class of snake – di vipers – dey rely more on haemotoxins, wey dey attack di blood, rather dan neurotoxins. In total around one dozen broad classes of toxin in snake venom, wey also include cytotoxins dey directly kill cells. "I think in di next 10 or 15 years we go get somtin effective against each one of dis toxin classes," Prof Peter Kwong, one of di researchers for Columbia University, tok. And di hunt continue inside Oga Friede blood samples. "Tim antibodies dey really quite extraordinary - e bin teach im immune system to get dis veri, veri broad recognition," Prof Kwong tok. Di ultimate hope na to get either single anti-venom wey fit do evritin, or one injection for elapids and one for vipers. Prof Nick Casewell, na di head of di centre for snakebite research and interventions for di Liverpool School of Tropical Medicine - e tok say di breadth of protection report bin dey unusual and provide "strong piece of evidence" wey get feasible approach. "No doubt say dis work move di field forward in exciting direction." But e caution say "plenti work still dey to do" and di anti-venom still go need extensive testing bifor dem fit use am in pipo. But for Oga Friede, reaching dis stage "make me feel good". "I dey do somtin good for humanity and e bin dey veri important to me. I dey proud of am. E dey pretty cool."


The Independent
2 hours ago
- The Independent
Woman kept on life support for months due to pregnancy finally laid to rest
Adriana Smith, an Atlanta mother and nurse, has finally been laid to rest, months after she was declared brain-dead after suffering a catastrophic stroke while eight weeks pregnant. The 31-year-old was kept on life support due to Georgia 's anti-abortion law, which grants personhood rights to a fetus, until her son, Chance, was delivered prematurely by emergency C-section. Smith's life support was turned off in mid-June and her funeral was held at Fairfield Baptist Church, just outside Atlanta, on Saturday. Her case has become a focal point for discussions on the impact of state-level abortion bans in medical emergencies and questions surrounding fetal personhood. Advocates and family members, including Democratic State Rep. Park Cannon, are pushing for 'Adriana's Law' to ensure individuals retain agency over their medical decisions, even while pregnant.
.jpg%3Ftrim%3D0%2C0%2C0%2C0%26width%3D1200%26height%3D800%26crop%3D1200%3A800&w=3840&q=100)

The Independent
6 hours ago
- The Independent
Funeral held for Georgia woman kept on life support until baby could be delivered: ‘Adriana's voice will be heard'
Adriana Smith, the Atlanta mother who was declared brain-dead but kept medically alive under Georgia's anti-abortion law, has been laid to rest. Smith, who turned 31 while on life support, suffered a catastrophic stroke in February and was declared brain-dead at eight weeks pregnant, but her family had no choice but to keep her alive until doctors delivered her son by emergency C-section. The case has become a lightning rod for the impact of state-level abortion bans in medical emergencies and has given rise to questions about fetal personhood. The 'vague' language of Georgia's LIFE Act, which doesn't clearly address cases of brain death, left Smith's family to navigate legal and medical complications during a devastating time, according to advocates. At Smith's funeral Saturday at Fairfield Baptist Church in Lithonia, just outside of Atlanta, loved ones addressed the difficulty of the nurse's death and vowed her voice 'will be heard,' 11Alive reports. 'Adriana's life mattered and we're gonna make sure ... from this house to the state house to Washington, D.C., that Adriana's voice will be heard,' Evangelist Triana Arnold James told the congregation, according to the outlet. Democratic State Rep. Park Cannon also rallied behind enacting 'Adriana's Law,' which she said would 'affirm that individuals retain agency over their bodies and medical decisions even under restrictive fetal personhood regimes.' 'We believe bodily autonomy should be upheld in Georgia by enacting Adriana's Law,' Cannon said. Smith's younger sister Naya spoke at the service, where she praised her sibling's 'love, kindness and wisdom.' In a poignant tribute at the end of the service, the Atlanta Metropolitan Nursing Honor Guard formally relieved Smith of her duties as a nurse and recited the 'final call of duty' in her honor, 11Alive reported. Smith's son Chance was born prematurely earlier this month, weighing about 1 pound 13 ounces. He is still in a neonatal intensive care unit. Smith has another 7-year-old son. Smith's mother, April Newkirk, said that doctors told her Georgia's anti-abortion law required that her daughter remain on life support until the fetus was able to survive outside the womb. The law was among a wave of anti-abortion measures enacted in Republican-led states after the Supreme Court revoked a constitutional right to abortion care by overturning the landmark Roe v Wade ruling in 2022. Georgia's law restricts abortion once cardiac activity is detected, or at roughly six weeks of pregnancy, before most women know they are pregnant. The law also grants personhood rights to a fetus, effectively providing the same full rights and legal protections as a person. 'I'm not saying we would have chosen to terminate her pregnancy. But I'm saying we should have had a choice,' Newkirk told 11Alive in a previous interview. Newkirk felt the same way after Chance's birth. 'I think all women should have a choice about their body,' she said. 'And I think I want people to know that.' Smith's loved ones gathered on June 15 to mark her 31st birthday and celebrate her life. Her life support machine was turned off a few days later.